Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
multiple sclerosis
Biotech
Zenas autoimmune drug prompts 95% drop in lesions in MS study
Zenas Biopharma’s lead autoimmune drug has been tied to a 95% reduction in a type of brain lesions over 12 weeks in a phase 2 MS study.
James Waldron
Oct 27, 2025 9:25am
Diabetes drug soothes brain inflammation in female mice with MS
Oct 15, 2025 6:16pm
Sanofi's troubled MS hopeful tolebrutinib hit by FDA delay
Sep 22, 2025 8:00am
Thermo Fisher debuts protein panel for neurodegeneration R&D
Sep 16, 2025 12:00pm
Contineum shifts cash from MS to lung disease showdown with BMS
Aug 6, 2025 9:51am
Roche links BTK drug to low relapse rate across 96-week MS trial
May 30, 2025 5:19am
